Immunic Inc chief scientific officer Dr Hella Kohlhof talked with Proactive's Stephen Gunnion about the company’s ongoing development of a treatment for multiple sclerosis (MS), a chronic inflammatory disease affecting the central nervous system.
Marking World Brain Day on July 22, Kohlhof explained that MS often affects young adults, impairing brain function and mobility during critical life stages. She noted the importance of early diagnosis and intervention, which is becoming more feasible through improved diagnostic tools, including biomarkers and imaging techniques.
Discussing Immunic’s research, Kohlhof said the company is focused on identifying the pathways that drive MS progression. The company's lead compound, vidofludimus calcium, is being tested in both relapsing and progressive forms of MS. The ENSURE phase 3 trial in relapsing MS has enrolled over 2,200 patients and is expected to deliver topline results by the end of 2026. Additionally, data from the phase 2 CALLIPER trial in progressive MS showed a positive impact on delaying confirmed disability worsening.
Kohlhof emphasized the goal of combining anti-inflammatory action with neuroprotective effects. “We want to protect the brain functions and help people to stay active, independent and engaged in their lives for as long as possible,” she said.
Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content.
#Immunic #MultipleSclerosis #MSResearch #VidofludimusCalcium #Neuroprotection #BrainHealth #MSAwareness #ClinicalTrials #ProgressiveMS #RelapsingMS
